We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Tecan’s Infinite® M1000 and a Plate of Live Fish

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Tecan’s Infinite® M1000 multimode microplate reader has enabled scientists in the Department of Cellular Biology and Anatomy at Georgia Health Sciences University (GHSU), USA, to develop a high throughput system for reporter-based drug screening assays in living zebrafish disease models.

Dr Jeff Mumm, Assistant Professor at GHSU, explained: “Quantitative microplate reader systems have revolutionized the pace of drug discovery, enabling the development of reporter-based in vitro and in silico assays that allow high throughput screening (HTS). However, biological validation has become a bottleneck in the drug discovery process, due to a lack of HTS-compatible in vivo assay platforms. Quantifying reporter levels in living zebrafish provides a versatile means of alleviating this road block.”

“The flexibility of the Infinite M1000 has allowed us to develop a simple and cost-effective automated screening method based on fluorescent or luminescent reporter detection in live zebrafish. Using this method we have been able to quantify the loss and regeneration of targeted cells in zebrafish disease models, as well as small molecule-induced changes in disease-linked molecular signaling pathways. High signal to noise ratios allow us to monitor changes in individual fish - which accounts for wide reporter level variance across populations by normalizing signals to each individual’s ground state - enabling us to detect long-term changes over several days. This powerful technique will benefit a wide variety of high throughput chemical and genetic screens in live zebrafish, potentially accelerating the validation of new drugs.”